CAS NO: | 1391076-61-1 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | GLPG0974 is afree fatty acid receptor-2 (FFA2/GPR43)antagonist with anIC50of 9 nM. | ||||||||||||||||
IC50& Target | IC50: 9 nM (GPR43)[1] | ||||||||||||||||
体外研究 (In Vitro) | GLPG0974 is able to inhibit acetate-induced neutrophil migration stronglyin vitroand demonstrates ability to inhibit a neutrophil-based pharmacodynamic (PD) marker, CD11b activation-specific epitope [AE], in a human whole blood assay[1]. | ||||||||||||||||
体内研究 (In Vivo) | GLPG0974 shows excellent pharmacokinetic properties in rat with a bioavailability of 47% and a linear increase of the plasma exposure after oral dosing at 5 and 30 mg/kg. The extended half-life observed following the increase of oral dose is consistent with the project objective to obtain long target coverage in human[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 485.00 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C25H25ClN2O4S | ||||||||||||||||
CAS 号 | 1391076-61-1 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 200 mg/mL(412.37 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|